Royalty Pharma Buys Pfizer Royalty for $2.25B
Ticker: RPRX · Form: 8-K · Filed: Sep 27, 2024 · CIK: 1802768
| Field | Detail |
|---|---|
| Company | Royalty Pharma PLC (RPRX) |
| Form Type | 8-K |
| Filed Date | Sep 27, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $100 million, $400 million, $2 billion, $25 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, royalty-deal, pharmaceutical
TL;DR
Royalty Pharma dropping $2.25B on Pfizer royalties - deal closes Q4.
AI Summary
Royalty Pharma plc announced on September 26, 2024, that it has entered into a definitive agreement to acquire a royalty interest in certain products from Pfizer Inc. for an upfront payment of $2.25 billion. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
Why It Matters
This significant acquisition by Royalty Pharma demonstrates continued investment in pharmaceutical royalties and could impact future revenue streams for both companies.
Risk Assessment
Risk Level: medium — The acquisition involves a substantial financial commitment and is subject to closing conditions, introducing execution and integration risks.
Key Numbers
- $2.25B — Acquisition Price (Upfront payment to Pfizer for royalty interests.)
Key Players & Entities
- Royalty Pharma plc (company) — Registrant
- Pfizer Inc. (company) — Seller of royalty interest
- $2.25 billion (dollar_amount) — Upfront payment for royalty interest
- September 26, 2024 (date) — Date of definitive agreement
- Q4 2024 (date) — Expected closing period
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is to report a material event, specifically Royalty Pharma plc's entry into a definitive agreement to acquire a royalty interest from Pfizer Inc.
Who are the main parties involved in the transaction?
The main parties are Royalty Pharma plc, the acquirer, and Pfizer Inc., the seller of the royalty interest.
What is the financial value of the agreement?
Royalty Pharma plc will make an upfront payment of $2.25 billion for the royalty interest.
When is the transaction expected to be completed?
The transaction is expected to close in the fourth quarter of 2024.
Are there any conditions to closing the deal?
Yes, the transaction is subject to customary closing conditions.
Filing Stats: 843 words · 3 min read · ~3 pages · Grade level 13.6 · Accepted 2024-09-27 08:39:00
Key Financial Figures
- $0.0001 — red Class A Ordinary Shares, par value $0.0001 per share RPRX The Nasdaq Stock Mar
- $100 million — "Royalty Pharma" or the "Company") paid $100 million upfront with up to $400 million in addi
- $400 million — ") paid $100 million upfront with up to $400 million in additional payments contingent on th
- $2 billion — xchange for a 3% royalty on sales up to $2 billion annually, after which threshold Royalty
- $25 million — lty. Royalty Pharma will pay PureTech a $25 million milestone as a result of this approval.
Filing Documents
- d889954d8k.htm (8-K) — 26KB
- 0001193125-24-227407.txt ( ) — 142KB
- rprx-20240926.xsd (EX-101.SCH) — 3KB
- rprx-20240926_lab.xml (EX-101.LAB) — 17KB
- rprx-20240926_pre.xml (EX-101.PRE) — 11KB
- d889954d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this Form 8-K unless stated otherwise, and neither the delivery of this Form 8-K at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This Form 8-K contains statements that constitute "forward-looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "target," "forecast," "guidance," "goal," "predicts," "project," "potential" or "continue," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of th
SIGNATURES
SIGNATURES Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ROYALTY PHARMA PLC Date: September 27, 2024 By: /s/ Terrance Coyne Terrance Coyne Chief Financial Officer